Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs when men start ADT.

Key facts

Study ID

NCT01607879

Run by

Medical College of Wisconsin

People needed

48

Starts

2014-03-01

Expected to finish

2021-02-16

Last updated by the study team

2023-09-22

Who can join

Age: 60 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed adenocarcinoma of the prostate
• Age 60 years or older
• Patients with asymptomatic or minimally symptomatic prostate cancer for which they are about to start androgen deprivation therapy (ADT) per provider recommendation
• Asymptomatic or minimally symptomatic (as judged by treating physician) metastases allowed
• Men receiving ADT for localized prostate cancer are allowed
• Patient able to give informed consent.

You may not qualify if…

• Patient already on ADT
• Patients who are visiting clinic for a second opinion only
• Patients with a diagnosis of dementia
• Patients with a diagnosis of a neuromuscular disorder (i.e. multiple sclerosis)

Where it is running

• Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.